SI2079443T1 - Dual action, inhaled formulations providing both an immediate and sustained release profile - Google Patents

Dual action, inhaled formulations providing both an immediate and sustained release profile

Info

Publication number
SI2079443T1
SI2079443T1 SI200731557T SI200731557T SI2079443T1 SI 2079443 T1 SI2079443 T1 SI 2079443T1 SI 200731557 T SI200731557 T SI 200731557T SI 200731557 T SI200731557 T SI 200731557T SI 2079443 T1 SI2079443 T1 SI 2079443T1
Authority
SI
Slovenia
Prior art keywords
immediate
sustained release
release profile
dual action
formulations providing
Prior art date
Application number
SI200731557T
Other languages
Slovenian (sl)
Inventor
David C. Cipolla
James Blanchard
Original Assignee
Aradigm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aradigm Corporation filed Critical Aradigm Corporation
Publication of SI2079443T1 publication Critical patent/SI2079443T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731557T 2006-10-24 2007-10-23 Dual action, inhaled formulations providing both an immediate and sustained release profile SI2079443T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86275306P 2006-10-24 2006-10-24
EP07867260.7A EP2079443B1 (en) 2006-10-24 2007-10-23 Dual action, inhaled formulations providing both an immediate and sustained release profile
PCT/US2007/022424 WO2008063341A2 (en) 2006-10-24 2007-10-23 Dual action, inhaled formulations providing both an immediate and sustained release profile

Publications (1)

Publication Number Publication Date
SI2079443T1 true SI2079443T1 (en) 2014-12-31

Family

ID=39430258

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731557T SI2079443T1 (en) 2006-10-24 2007-10-23 Dual action, inhaled formulations providing both an immediate and sustained release profile

Country Status (12)

Country Link
US (2) US8268347B1 (en)
EP (3) EP2789330A1 (en)
JP (2) JP5254239B2 (en)
CN (2) CN104666248B (en)
AU (1) AU2007322224B2 (en)
CA (1) CA2667494C (en)
DK (1) DK2079443T3 (en)
ES (1) ES2520028T3 (en)
PL (1) PL2079443T3 (en)
PT (1) PT2079443E (en)
SI (1) SI2079443T1 (en)
WO (1) WO2008063341A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
PT1962805T (en) 2005-12-08 2016-10-05 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2009091531A2 (en) * 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
TW201010708A (en) 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
AU2009302042A1 (en) * 2008-10-07 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
EP2515935A4 (en) * 2009-12-22 2013-08-28 Kalobios Pharmaceuticals Inc A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CN102892412B (en) 2010-03-12 2015-09-30 博格制药有限责任公司 The iv formulation of coenzyme Q10 (CoQ10) and using method thereof
CN102309448B (en) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof
JP6194248B2 (en) * 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド Sustained release formulations of non-steroidal anti-inflammatory drugs
IT1405998B1 (en) * 2010-12-09 2014-02-06 Bionest Ltd MULTIPURPOSE GEL AGAINST THE VAGINAL DRYNESS WITH A DIRECT AND DELAYED EFFECT
US10973763B2 (en) * 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
WO2013057208A1 (en) * 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
JP6285865B2 (en) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ Assays and methods for selecting treatment regimens for subjects with depression
JP6402097B2 (en) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド System for treating pulmonary infections
WO2014058974A1 (en) * 2012-10-10 2014-04-17 Emory University Methods of managing inflammation using glycolysis pathway inhibitors
MX2015006681A (en) 2012-11-29 2016-04-06 Insmed Inc Stabilized vancomycin formulations.
AU2014340568B2 (en) 2013-10-22 2017-02-02 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
KR20160144404A (en) 2014-04-08 2016-12-16 아라다임 코포레이션 Liposomes that form drug nanocrystals after freeze-thaw
CA2943049A1 (en) 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
WO2015175939A1 (en) 2014-05-15 2015-11-19 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10987048B2 (en) 2014-08-13 2021-04-27 Elwha Llc Systems, methods, and devices to incentivize inhaler use
US10245393B2 (en) 2014-08-13 2019-04-02 Elwha Llc Methods, systems, and devices related to a supplemental inhaler
US10765817B2 (en) 2014-08-13 2020-09-08 Elwha, Llc Methods, systems, and devices related to delivery of alcohol with an inhaler
WO2016179365A1 (en) * 2015-05-05 2016-11-10 Musc Foundation For Research Development Nanocarriers for delivery of alpha-1-antitrypsin
TWI609701B (en) * 2016-01-05 2018-01-01 國立交通大學 Compound prescription colloidal eyedrop gel and methods of making the same
US20170355933A1 (en) * 2016-06-09 2017-12-14 The Procter & Gamble Company Cleaning compositions including nuclease enzyme and malodor reduction materials
EA031933B1 (en) * 2016-08-05 2019-03-29 Общество С Ограниченной Ответственностью "Научно-Производственный Центр Пробиотех" Veterinary biological preparation, method of producing the same (embodiments), and method for treatment of nodular dermatitis in bovine cattle (embodiments)
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
US20190282565A1 (en) * 2018-03-19 2019-09-19 Gui-Bai Liang Methods and Compositions for Treating Idiopathic Pulmonary Fibrosis
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3784213B1 (en) 2018-04-23 2023-09-06 InspirMed Corp. Inhalable liposomal sustained release composition for use in treating pulmonary diseases
CN111249251A (en) * 2018-12-03 2020-06-09 华中农业大学 Enrofloxacin chitosan nanoparticles
CN113613638A (en) * 2019-02-22 2021-11-05 希拉治疗公司 Inhalable therapeutic agents
EP3991722A4 (en) * 2019-06-28 2022-10-05 Jiangsu Hengrui Medicine Co., Ltd. Sustained-release lipid composition and preparation method therefor
CN113018443B (en) * 2019-12-27 2022-09-13 海南斯达制药有限公司 Pharmaceutical composition for treating respiratory system diseases and preparation method thereof
CN113116823B (en) * 2019-12-30 2024-02-20 江苏恒瑞医药股份有限公司 Liposome and preparation method thereof
CN111420024B (en) * 2020-04-07 2023-10-03 中国科学院深圳先进技术研究院 Application of bacillus phthalein A in preparing medicament for preventing and treating coronavirus
CN112076193B (en) * 2020-10-13 2021-10-26 苏州大学 Application of mequindox in preparation of medicine for treating and/or preventing diseases taking T-type calcium channel as treatment target

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2000414A (en) 1932-08-10 1935-05-07 Ig Farbenindustrie Ag Explosive composition
US4142026A (en) 1977-04-22 1979-02-27 Zordan Macario J Dry cell adapter
DE2848503C2 (en) 1978-11-08 1983-05-05 Alcan Aluminiumwerk Nürnberg GmbH, 6000 Frankfurt Machine housing with a component that has a relatively small wall thickness
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IL83567A (en) 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
US4957998A (en) 1988-08-22 1990-09-18 Pharmaceutical Delivery Systems, Inc. Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
ATE92107T1 (en) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US6623671B2 (en) 1990-10-05 2003-09-23 Royden M. Coe Liposome extrusion process
CA2079444C (en) 1991-02-14 2004-02-03 Rimona Margalit Binding of recognizing substances to liposomes
US5176907A (en) 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5367051A (en) 1993-07-22 1994-11-22 Sri International Amine-containing polymerizable monomers and polymers functionalized with fullerenes to provide polymers with high temperature stability
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
DK0678017T3 (en) 1993-11-05 1998-10-19 Amgen Inc Liposome preparation and material encapsulation method
JPH08510761A (en) 1994-03-07 1996-11-12 ザ・ダウ・ケミカル・カンパニー Biologically active and / or targeted dendrimer complex
SE518578C2 (en) 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
WO1996032930A1 (en) * 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
CA2250219C (en) 1996-03-28 2008-10-07 Hayat Onyuksel Materials and methods for making improved liposome compositions
CA2174803C (en) 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2215716C (en) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Aerosol delivery of liposome-encapsulated fluoroquinolone
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4741727B2 (en) * 1998-05-27 2011-08-10 ユーロ−セルティーク エス．エイ． Formulation for applying anti-inflammatory agent, especially disinfectant and / or wound healing promoter to lower respiratory tract
US6277413B1 (en) 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
DE69935154T2 (en) * 1998-11-12 2007-10-25 Inc. Transave INHALATION SYSTEM
IL143104A (en) 1998-11-13 2005-09-25 Optime Therapeutics Inc Method and apparatus for liposome production
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
JP2003503367A (en) 1999-06-11 2003-01-28 シアウォーター・コーポレイション Hydrogels derived from chitosan and poly (ethylene glycol) or related polymers
WO2001000173A1 (en) * 1999-06-24 2001-01-04 Kyowa Hakko Kogyo Co., Ltd. Method of regulating leakage of drug encapsulated in liposomes
AU6366700A (en) 1999-07-21 2001-02-13 Penn State Research Foundation, The Polyphosphazene polymers
DE19954843C2 (en) 1999-11-09 2003-11-20 Novosom Ag Process for encapsulating proteins or peptides in liposomes, liposomes produced by the process and their use
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002092661A1 (en) 2001-05-11 2002-11-21 Ap Pharma, Inc. Peg-poe, peg-poe-peg, and poe-peg-poe block copolymers
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DK2363114T3 (en) 2002-10-29 2015-06-22 Insmed Inc Sustained release of anti-infective agents
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
JP2007500239A (en) * 2003-05-30 2007-01-11 アルザ・コーポレーシヨン Method of pulmonary administration of drugs
FR2856844B1 (en) 2003-06-24 2006-02-17 Commissariat Energie Atomique HIGH PERFORMANCE CHIP INTEGRATED CIRCUIT
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
EP1711610A2 (en) 2004-01-28 2006-10-18 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
PT1962805T (en) * 2005-12-08 2016-10-05 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile

Also Published As

Publication number Publication date
CA2667494A1 (en) 2008-05-29
JP2013116909A (en) 2013-06-13
EP2789330A1 (en) 2014-10-15
ES2520028T3 (en) 2014-11-11
JP2010507658A (en) 2010-03-11
CN104666248B (en) 2017-11-03
CN104666248A (en) 2015-06-03
JP5254239B2 (en) 2013-08-07
EP2079443B1 (en) 2014-08-27
EP2759292A1 (en) 2014-07-30
WO2008063341A3 (en) 2008-10-16
PT2079443E (en) 2014-11-26
AU2007322224A1 (en) 2008-05-29
WO2008063341A2 (en) 2008-05-29
PL2079443T3 (en) 2015-02-27
EP2079443A2 (en) 2009-07-22
CA2667494C (en) 2015-05-19
US20120282328A1 (en) 2012-11-08
JP5797217B2 (en) 2015-10-21
CN101553209A (en) 2009-10-07
US8414915B2 (en) 2013-04-09
DK2079443T3 (en) 2014-12-08
US8268347B1 (en) 2012-09-18
AU2007322224B2 (en) 2012-05-17
EP2079443A4 (en) 2012-03-07
US20120244206A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
EP2079443A4 (en) Dual action, inhaled formulations providing both an immediate and sustained release profile
GB2435419B (en) Formulations
IL194688A0 (en) Rapid acting and long acting insulin combination formulations
IL184460A0 (en) Sustained release pharmaeutical formulations
HK1200092A1 (en) Sustained release formulations
EP2046930A4 (en) Rhamnolipid-based formulations
IL188964A0 (en) Sustained drug release composition
HRP20130109T1 (en) Caspofungin formulations
EP2046290A4 (en) Aqueous dronabinol formulations
GB0605780D0 (en) Formulations
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
IL198168A0 (en) Robust sustained release formulations
HK1180949A1 (en) Long lasting drug formulations
EP2090300A4 (en) Sustained release preparation
GB0718409D0 (en) Formulations
GB0610336D0 (en) Formulations
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
GB0503509D0 (en) An improved delivery agent
EP2345660A4 (en) Anti-xdr-tb agent, anti-mdr-tb agent, and combined anti-tuberculous agent
GB0705395D0 (en) Breath deodoriser
GB0716700D0 (en) Inhaled combination theraphy
GB0718404D0 (en) Formulations
IL177596A0 (en) Inhalation formulations
GB0603380D0 (en) Formulations
GB0603981D0 (en) Tissue-adhesive formulations